Heron Therapeutics Inc
Suletud
SektorTervishoid
0.4
Ülevaade
Aktsiahinna muutus
24h
Min
0.4
Max
0.41
Sissetulek | -5.2M -8.1M |
|---|---|
Müük | -5.9M 35M |
Aktsiakasum | -0.04 |
Kasumimarginaal | -23.367 |
Töötajad | 128 |
EBITDA | -4M -4.8M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +400% upside |
Järgmine tulemuste avaldamine | 7. aug 2026 |
|---|
Turukapital | -144M 86M |
|---|---|
Eelmine avamishind | 0.4 |
Eelmine sulgemishind | 0.4 |
Heron Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Heron Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
400% tõus
12 kuu keskmine prognoos
Keskmine 2 USD 400%
Kõrge 2 USD
Madal 2 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
